• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    11/4/25 4:06:48 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    false 0001433607 0001433607 2025-11-04 2025-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): November 4, 2025

     

    InspireMD, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-35731   26-2123838

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    6303 Waterford District Drive, Suite 215

    Miami, Florida

      33126
    (Address of Principal Executive Offices)   (Zip Code)

     

    (888) 776-6804

    (Registrant’s Telephone Number, Including Area Code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition

     

    On November 4, 2025, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 7.01 Regulation FD Disclosure.

     

    On November 4, 2025, the Company made available an updated investor presentation. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on the Company’s website https://www.inspiremd.com/en/investors/.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    99.1   Press release, dated November 4, 2025 (furnished herewith pursuant to Item 2.02)
    99.2   Investor Presentation November 2025 (furnished herewith pursuant to Item 7.01)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INSPIREMD, INC.
         
    Date: November 4, 2025 By: /s/ Michael Lawless
      Name: Michael Lawless
      Title: Chief Financial Officer

     

     

     

     

    Get the next $NSPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    SEC Filings

    View All

    SEC Form 10-Q filed by InspireMD Inc.

    10-Q - InspireMD, Inc. (0001433607) (Filer)

    11/10/25 4:06:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    11/4/25 4:06:48 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    9/17/25 8:00:33 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roubin Gary S was granted 48,000 shares, increasing direct ownership by 8% to 656,425 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    10/9/25 4:05:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    New insider Dearen Danny L. claimed ownership of 58,017 shares (SEC Form 3)

    3 - InspireMD, Inc. (0001433607) (Issuer)

    9/24/25 4:00:13 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Kester Thomas J was granted 37,815 shares, increasing direct ownership by 9% to 458,573 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    9/17/25 4:20:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kester Thomas J bought $74,998 worth of shares (30,991 units at $2.42), increasing direct ownership by 8% to 420,758 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    CEO and President Slosman Marvin bought $24,999 worth of shares (10,330 units at $2.42), increasing direct ownership by 0.43% to 2,420,866 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:21 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $50,000 worth of shares (20,661 units at $2.42) (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:19 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care